Non-melanoma skin cancer includes several types of cutaneous tumors, with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) as the commonest. Among the available therapeutic options, surgical excision is the mainstay of treatment for both tumors. However, tumor features and patients’ comorbidities may limit the use of these techniques, making the treatment challenging. As regards BCC, even if hedgehog inhibitors revolutionized the therapeutic scenario, there are still patients unresponsive or intolerant to these drugs. In this context, cemiplimab has been approved as second-line treatment. As regards SCC, cemiplimab was the first systemic therapy approved. The objective of this manuscript was to investigate the efficacy and safety of cemiplimab for the management of BCC and cSCC. Cemiplimab has a durable and significant effect for the management of BCC and CSCC, with a favorable safety profile. Different specialists including oncologists, radiologists, dermatologists, and surgeons are required to guarantee an integrated approach, leading to the best management of patients. Moreover, the collaboration among specialists will allow them to best manage the TEAEs, reducing the risk of treatment suspension or discontinuation. Certainly, ongoing studies and more and more emerging real-world evidence, will allow us to better characterize the role of cemiplimab for the management of advanced non-melanoma skin cancer.
非黑色素瘤皮肤癌包含多种皮肤肿瘤类型，其中以基底细胞癌和皮肤鳞状细胞癌最为常见。在现有治疗方案中，手术切除是这两种肿瘤的主要治疗手段。然而，肿瘤特征及患者合并症可能限制这些技术的应用，使治疗面临挑战。就基底细胞癌而言，尽管刺猬抑制剂革新了治疗格局，仍存在对这类药物无应答或不耐受的患者群体。在此背景下，西米普利单抗获批作为二线治疗方案。对于鳞状细胞癌，西米普利单抗则是首个获批的全身性疗法。本文旨在探讨西米普利单抗治疗基底细胞癌与皮肤鳞状细胞癌的疗效与安全性。西米普利单抗对这两种肿瘤具有持久显著的疗效，且安全性良好。需要肿瘤科、放射科、皮肤科及外科等多学科专家协同实施整合诊疗策略，以实现患者的最佳管理。此外，多学科协作有助于优化治疗相关不良事件的管理，降低治疗暂停或终止风险。当前持续开展的研究及日益丰富的真实世界证据，必将进一步明确西米普利单抗在晚期非黑色素瘤皮肤癌治疗中的临床价值。
肿瘤(癌症)患者之家